← 홈

CGT · 림프종

308개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 308개
CGTBiologicstaleMedical College of WisconsinPhase 1

LV20.19 CAR T cells (LV20.19 CAR T cells)

Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstalePeking UniversityPhase 1

MC-19PD1 CAR-T cells (MC-19PD1 CAR-T cells)

Lymphoma · Lymphoma

#Lymphoma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 25%임상시험 1상태 ACTIVE
CGTBiologicstaleHebei Senlang Biotechnology Inc…Phase 2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T (Nanobody-Based CD19/CD22 Tandem Dual CAR-T)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleTimmune Biotech Inc.Phase 1

Novel CAR-T (Novel CAR-T)

B-cell Non Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleM.D. Anderson Cancer CenterPhase 2

ONC-PluReceptor NK cells (ONC-PluReceptor NK cells)

Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstalePrecision BioSciences, Inc.Phase 2

PBCAR20A (PBCAR20A)

Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 6%임상시험 1상태 ACTIVE
CGTBiologicstalePinze Lifetechnology Co. Ltd.Phase 1

PZ01 CAR-T cells (PZ01 CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstalePell Bio-Med Technology Co., Lt…Preclinical

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Diffuse Large B Cell Lymphoma; Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

RNA anti-CD19 CAR T cells (RNA anti-CD19 CAR T cells)

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleEden BioCell Ltd.Phase 1

RPM CD19-mbIL15-CAR-T cells (RPM CD19-mbIL15-CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma, Relapsed · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 DISCONTINUED
CGTBiologicstaleXinqiao Hospital of ChongqingPhase 1

Retroviral vector-transduced autologous T cells to express CD22-specific CARs (Retroviral vector-transduced autologous T cells to express CD22-specific CARs)

Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Follicular Lymphoma · CD22

#CD22#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleVittoria BiotherapeuticsPhase 1

Senza5 CART5 (Senza5 CART5)

T Cell Non-Hodgkin Lymphoma · T Cell Non-Hodgkin Lymphoma

#TCellNon-HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleInstitute of Hematology & Blood…Phase 1

Sup19 CAR-T (Sup19 CAR-T)

B-Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia/Lymphoma · B-Acute Lymphoblastic Leukemia

#B-AcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleChinese PLA General HospitalPhase 2

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T))

Non-hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleChinese PLA General HospitalPhase 1

TP53-EphA-2-CAR-DC (TP53-EphA-2-CAR-DC)

Solid Tumor, Adult; Lymphoma · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleEdiGene Inc.Phase 2

TRAC and Power3 (SPPL3, TRAC and Power3, TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T))

Non Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstale920th Hospital of Joint Logisti…Phase 1

Target CD7 CAR-T cells (Target CD7 CAR-T cells)

T-cell Acute Lymphoblastic Leukemia; T-lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED

14 / 16 페이지

← 이전다음 →